Skip to main content
Retour
Watch Compare

Lyra Therapeutics, Inc.

Qualité des données : 100%
LYRA
OTC Manufacturing Measuring & Analyzing Instruments
0,65 €
▲ 0,12 € (22,64%)
Cap. Boursière: 870 402,0
Prix
0,49 €
Cap. Boursière
870 402,0
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Revenue grew 8,71% annually over 5 years — modest growth
Negative free cash flow of -28,98 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 82,76%

Croissance

Revenue Growth (5Y)
8,71%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)-74,05%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-64,80%
Net Margin-7266,08%
Op. Margin-7794,47%

Sécurité

Debt / Equity
N/A
Current Ratio2,43
Interest CoverageN/A

Valorisation

PE (TTM)
-0,03
Au-dessus de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E 0,0 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % -7266,1 -41,5
Rev Growth 5Y % 8,7 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -74,05% Revenue Growth (3Y) -49,46%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 8,71% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 398 000,0 Net Income (TTM) -28,92 M
ROE N/A ROA -60,07%
Gross Margin N/A Operating Margin -7794,47%
Net Margin -7266,08% Free Cash Flow (TTM) -28,98 M
ROIC -64,80% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,43
Interest Coverage N/A Asset Turnover 0,01
Working Capital 13,54 M Tangible Book Value -4,33 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,03 Forward P/E N/A
P/B Ratio N/A P/S Ratio 2,19
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -3328,92%
Market Cap 870 402,0 Enterprise Value -21,18 M
Per Share
EPS (Diluted TTM) -18,62 Revenue / Share 0,22
FCF / Share -16,33 OCF / Share -16,26
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 29,15% FCF Conversion 100,19%
SBC-Adj. FCF -32,24 M Growth Momentum -82,76

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 398 000,0 1,53 M 1,56 M 1,36 M 285 000,0
Net Income -28,92 M -93,44 M -62,68 M -55,28 M -43,51 M
EPS (Diluted) -18,62 -1,43 -1,26 -1,83 —
Gross Profit — — — — —
Operating Income -31,02 M -96,35 M -67,12 M -56,31 M -43,62 M
EBITDA — — — — —
R&D Expenses 18,41 M 43,77 M 48,03 M 38,80 M 29,69 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 11 000,0 39 000,0 59 000,0 13 000,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 36,11 M 66,35 M 142,60 M 109,97 M 54,87 M
Total Liabilities 46,83 M 54,75 M 53,18 M 29,21 M 20,55 M
Shareholders' Equity -10,72 M 11,59 M 89,42 M 80,75 M 34,32 M
Total Debt — — — — —
Cash & Equivalents 15,89 M 40,58 M 22,35 M 32,55 M 45,75 M
Current Assets 16,27 M 43,03 M 104,82 M 100,83 M 47,92 M
Current Liabilities 9,52 M 12,63 M 19,60 M 14,47 M 18,25 M